205 related articles for article (PubMed ID: 32372672)
1. A metastatic intrahepatic cholangiocarcinoma treated with programmed cell death 1 inhibitor: a case report and literature review.
Zhang J; Wu L; Liu J; Lin M
Immunotherapy; 2020 Jun; 12(8):555-561. PubMed ID: 32372672
[TBL] [Abstract][Full Text] [Related]
2. Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade.
Liu X; Yao J; Song L; Zhang S; Huang T; Li Y
J Immunother Cancer; 2019 Aug; 7(1):204. PubMed ID: 31383016
[TBL] [Abstract][Full Text] [Related]
3. Intrahepatic Cholangiocarcinoma with High Microsatellite Instability and Tumor Mutation Burden That Responded Significantly to Pembrolizumab but Perforated within a Short Period.
Yamazaki S; Kubota K; Shimizu A; Notake T; Umemura K; Kamachi A; Goto T; Tomida H; Yamashita N; Sato M; Kanno H; Soejima Y
Intern Med; 2024 Apr; 63(8):1105-1112. PubMed ID: 37779076
[TBL] [Abstract][Full Text] [Related]
4. Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report.
Zhang Z; Zhang W; Wang H; Hu B; Wang Z; Lu S
Front Immunol; 2021; 12():744571. PubMed ID: 34603331
[TBL] [Abstract][Full Text] [Related]
5. Treatment of advanced intrahepatic cholangiocarcinoma with sintilimab combined with tegafur-gimeracil-oteracil potassium capsules (S-1): a case report.
Liu J; Wang C; Cao L; Li S
Ann Palliat Med; 2020 Mar; 9(2):497-503. PubMed ID: 32233637
[TBL] [Abstract][Full Text] [Related]
6. Microsatellite Instability-high Intrahepatic Cholangiocarcinoma with Portal Vein Tumor Thrombosis Successfully Treated with Pembrolizumab.
Naganuma A; Sakuda T; Murakami T; Aihara K; Watanuki Y; Suzuki Y; Shibasaki E; Masuda T; Uehara S; Yasuoka H; Hoshino T; Kudo T; Ishihara H; Ogawa T; Kitamoto Y; Ogawa A
Intern Med; 2020 Sep; 59(18):2261-2267. PubMed ID: 32536644
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of pembrolizumab in microsatellite instability-high locally advanced cholangiocarcinoma: a case report.
Toshida K; Itoh S; Yoshizumi T; Shimagaki T; Wang H; Kurihara T; Toshima T; Nagao Y; Harada N; Oki E; Nakamura Y; Yoshino T; Mori M
Clin J Gastroenterol; 2021 Oct; 14(5):1459-1463. PubMed ID: 34085164
[TBL] [Abstract][Full Text] [Related]
8. PD-1 Inhibitors Plus Capecitabine as Maintenance Therapy for Advanced Intrahepatic Cholangiocarcinoma: A Case Report and Review of Literature.
Wang Z; Zeng T; Li Y; Zhang D; Yuan Z; Huang M; Yang Y; Zhou W
Front Immunol; 2021; 12():799822. PubMed ID: 35003124
[TBL] [Abstract][Full Text] [Related]
9. Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurrent intrahepatic cholangiocarcinoma with bone metastasis: A case report and literature review.
Chen WX; Li GX; Hu ZN; Zhu P; Zhang BX; Ding ZY
Medicine (Baltimore); 2019 Nov; 98(45):e17832. PubMed ID: 31702638
[TBL] [Abstract][Full Text] [Related]
10. Effective Response of Intrahepatic Cholangiocarcinoma to Pembrolizumab: A Case Report.
Nakamura M; Ueno M; Hayami S; Kawai M; Miyamoto A; Suzaki N; Hirono S; Okada KI; Miyazawa M; Kitahata Y; Kobayashi R; Kojima F; Yamaue H
Anticancer Res; 2020 Jul; 40(7):4123-4129. PubMed ID: 32620661
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
[TBL] [Abstract][Full Text] [Related]
12. [A case of unresectable intrahepatic cholangiocarcinoma receiving sustainable pembrolizumab therapy].
Matsushita S; Ueo T; Minami R; Ozawa T; Matsumoto A; Kimura Y; Takeda Y; Okano A; Kusumi F; Ohana M
Nihon Shokakibyo Gakkai Zasshi; 2022; 119(4):360-367. PubMed ID: 35400689
[TBL] [Abstract][Full Text] [Related]
13. PD-1 blockade and radiotherapy combination for advanced Epstein-Barr virus-associated intrahepatic cholangiocarcinoma: a case report and literature review.
Liao CX; Deng CS; Liang X; Yang JC; Chen ZZ; Lin XY; Lin CF; Chen S; Wu SS
Front Immunol; 2023; 14():1239168. PubMed ID: 37753076
[TBL] [Abstract][Full Text] [Related]
14. Dramatic response to trastuzumab and paclitaxel in a patient with human epidermal growth factor receptor 2-positive metastatic cholangiocarcinoma.
Law LY
J Clin Oncol; 2012 Sep; 30(27):e271-3. PubMed ID: 22851567
[No Abstract] [Full Text] [Related]
15. Programmed death-1 inhibitor for occupational intrahepatic cholangiocarcinoma caused by chlorinated organic solvents.
Tanaka S; Kubo S
J Hepatobiliary Pancreat Sci; 2019 Jun; 26(6):242-243. PubMed ID: 30945442
[TBL] [Abstract][Full Text] [Related]
16. Intrahepatic Cholangiocarcinoma With Extrahepatic Metastasis and High Tumor Mutation Burden: Case of Complete Pathological Response to Cisplatin/Gemcitabine/Pembrolizumab.
Robinson MD; Wheatley R; Foster L; Jamdar S; Siriwardena AK; Lamarca A; Hubner R; Valle JW; McNamara MG
JCO Precis Oncol; 2024 Apr; 8():e2300572. PubMed ID: 38662981
[No Abstract] [Full Text] [Related]
17. Case report: Preliminary response to tislelizumab plus S-1 in patients with metastatic gallbladder carcinoma: A report of five cases and a literature review.
Zhang Y; Liu Y; Liu J; Liu T; Xiong H; Li W; Fu X; Zhou F; Liao S; Fang L; Liang B
Front Immunol; 2023; 14():1144371. PubMed ID: 37020545
[TBL] [Abstract][Full Text] [Related]
18. Durable response after discontinuation of pembrolizumab therapy for intrahepatic cholangiocarcinoma: a case report.
Eguchi S; Shinkawa H; Sato Y; Nakai K; Takemura S; Tanaka S; Amano R; Kimura K; Ohira G; Nishio K; Kinoshita M; Tauchi J; Miyazaki T; Ishihara A; Shirai D; Kubo S
Clin J Gastroenterol; 2021 Jun; 14(3):858-865. PubMed ID: 33811313
[TBL] [Abstract][Full Text] [Related]
19. A Case Report of Non-Bacterial Cystitis Caused by Immune Checkpoint Inhibitors.
Zhu S; Bian L; Lv J; Liu B; Shen J
Front Immunol; 2021; 12():788629. PubMed ID: 35003107
[TBL] [Abstract][Full Text] [Related]
20. Combining PD-1 Inhibitor with VEGF/VEGFR2 Inhibitor in Chemotherapy: Report of a Patient with End-Stage Cholangiocarcinoma and Review of Literature.
Ma Z; Li H; Liu L
Recent Pat Anticancer Drug Discov; 2021; 16(1):101-107. PubMed ID: 33390149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
